A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor

LESSONS LEARNED. The combination of pexidartinib and binimetinib was safe and tolerable and demonstrated encouraging signs of efficacy in two patients with advanced gastrointestinal stromal tumor (GIST) refractory to tyrosine kinase inhibitors (TKIs). Molecular profiling of GISTs at diagnosis and up...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Rosenbaum, Evan, Kelly, Ciara, D'Angelo, Sandra P., Dickson, Mark A., Gounder, Mrinal, Keohan, Mary L., Movva, Sujana, Condy, Mercedes, Adamson, Travis, Mcfadyen, Chloe R., Antonescu, Christina R., Hwang, Sinchun, Singer, Sam, Qin, Li‐Xuan, Tap, William D., Chi, Ping
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2019
Témata:
Clinical Trial Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795162/
https://ncbi.nlm.nih.gov/pubmed/31213500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0418
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky